Glaxo Group Limited patents

Ligands that bind tgf-beta receptor ii

The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure... Glaxo Group Limited

Methods for selecting protease resistant polypeptides

The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing... Glaxo Group Limited

Novel composition

The invention relates to non-aqueous dentrfrice compositions comprising a surfactant system. The surfactant system consists of a combination of surfactants i.e. a betaine and a taurate surfactant; or a betaine and an alkyl sulphate surfactant; or a betaine, a taurate and an alkyl sulphate surfactant.... Glaxo Group Limited

Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist

Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.... Glaxo Group Limited

Positive allosteric modulators of human melanocortin-4 receptor

Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.... Glaxo Group Limited

Anti-serum albumin binding variants

The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.... Glaxo Group Limited

2 substituted cephem compounds

The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.... Glaxo Group Limited

Process for separation of oligonucleotide of interest from a mixture

A method for separation of an oligonucleotide from a mixture using a biphasic mobile phase/stationary phase liquid-liquid chromatography system. A first mobile phase contains the oligonucleotide and the stationary phase contains an exchanger substance that removably binds to the target oligonucleotide. The mobile phase is caused to flow in contact... Glaxo Group Limited

Medicament dispenser

An inhalation device having at least one elongate medicament carrier including, but not limited to, a pair of sheets sealed together and a plurality of medicament powder doses positioned at spaced-apart locations between said sealed sheets, an outlet for a user to inhale from, and a mechanism for stepwise advancement... Glaxo Group Limited

Novel milk beverage composition comprising creatine

Ready to drink milk beverage compositions are described comprising creatine and an added protein such as whey protein, which have good creatine shelf life at ambient temperatures.... Glaxo Group Limited

Novel compounds

and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.... Glaxo Group Limited

Antigen binding proteins to oncostatin m (osm)

The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further... Glaxo Group Limited

2- (azaindol-2-yl) benzimidazoles as pad4 inhibitors

and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.... Glaxo Group Limited

Child-proof package

A package which can be torn open by a user, comprising a polymer film material having a preferential tearing direction and defining a cavity for a product, wherein the polymer film material incorporates a bias facilitating tearing along a tear line oriented in a direction other than its preferential tearing... Glaxo Group Limited

Novel compounds

The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.... Glaxo Group Limited

Antigen binding constructs

The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising... Glaxo Group Limited

Immunoglobulins

The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.... Glaxo Group Limited

Novel compounds

The invention is directed to certain novel compounds. Specifically, crystalline forms of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide and crystalline 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole, along with salts thereof.... Glaxo Group Limited